Literature DB >> 1651356

Requirements of class II-mediated B cell differentiation for class II cross-linking and cyclic AMP.

G A Bishop1.   

Abstract

Cells of the mouse B cell clone, CH12.LX, receive Ag-dependent differentiative signals through their surface membrane class II molecules. The present study was performed to determine the role of class II cross-linking and cAMP in the successful delivery of these signals. Delivery of differentiative signals by anti-Ek mAb was increased by further cross-linking with a secondary anti-isotype antibody. Intact or (Fab')2, but not Fab forms of anti-Ek successfully delivered the Ag-dependent differentiative signal. Inability of monovalent Fab fragments to deliver the signal could not be attributed to an inability to adequately bind Ek molecules. The requirement for cAMP for class II-mediated signaling was also examined, because previous studies have implicated elevated cAMP levels as necessary for class II signaling. Both Ag-dependent, Ek-mediated differentiation and the Ek-mediated inhibition of Ag-independent LPS-induced differentiation were inhibited by the adenyl cyclase inhibitor 2'5'ddA, although elevation of cAMP was not in itself sufficient to deliver the differentiative signal. Inhibition of LPS-induced differentiation could be mediated by mAb binding to either Ek, Abk, or Abb on CH12.LX or an Ab-bearing transfectant, CH12.ABB1. This inhibition was abrogated by 2'5'ddA in the case of Ek or Abb, both of which deliver Ag-dependent differentiative signals to CH12.LX cells. In the case of Abk, which does not deliver such signals to CH12.LX, 2'5'ddA did not abrogate anti-Abk-mediated inhibition of the LPS response. The effects of 2'5'ddA were reversed by the cAMP analog, dibutyryl cAMP, and Ag-dependent-induced differentiation of CH12.LX or CH12.ABB1 was accompanied by an increase in cAMP levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651356

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

2.  Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.

Authors:  John P Graham; Carissa R Moore; Gail A Bishop
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

3.  Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk.

Authors:  Xingguang Liu; Zhenzhen Zhan; Dong Li; Li Xu; Feng Ma; Peng Zhang; Hangping Yao; Xuetao Cao
Journal:  Nat Immunol       Date:  2011-03-27       Impact factor: 25.606

4.  Superactivation of an immune response triggered by oligomerized T cell epitopes.

Authors:  O Rötzschke; K Falk; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  TRAF5 negatively regulates TLR signaling in B lymphocytes.

Authors:  Claire M Buchta; Gail A Bishop
Journal:  J Immunol       Date:  2013-11-20       Impact factor: 5.422

Review 6.  Signaling by CD40 and its mimics in B cell activation.

Authors:  G A Bishop; B S Hostager
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

7.  Roles of the kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral mimic, LMP1.

Authors:  Kelly M Arcipowski; Gail A Bishop
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

8.  Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes.

Authors:  Ping Xie; Bruce S Hostager; Gail A Bishop
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

Review 9.  Immunological Functions of the Membrane Proximal Region of MHC Class II Molecules.

Authors:  Jonathan Harton; Lei Jin; Amy Hahn; Jim Drake
Journal:  F1000Res       Date:  2016-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.